Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide

Phase 3

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR (JHPCY)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

JHPCYPhase 3$38.2B

Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide Phase 3 Est. Readout

Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide• Advanced Gastroenteropancreatic Neuroendocrine Tumor220

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Advanced Gastroenteropancreatic Neuroendocrine Tumor

View Full Landscape

Drug Information

Target Indication

Advanced Gastroenteropancreatic Neuroendocrine Tumor

Clinical Trial

NCT05884255

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMAPending

Deqtynet

Positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine neoplasms (NENs).

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

JHPCY

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR

Biotechnology•North America•NASDAQ

Related Pipeline

JSKN003Phase 3

Advanced Solid Tumor

Irinotecan liposome、5-Fluorouracil、LeucovorinPhase 3

Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy

X0002 SprayPhase 3

KNEE OSTEOARTHRITIS

RocuroniumPhase 3

Neuromuscular Blockade

HRS-9190Phase 3

Neuromuscular Blockade

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts